3:43 PM
 | 
Aug 06, 2018
 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human antibodies and TCRs against tumor-specific antigens and bluebird will use its lentiviral vector technology to further develop the therapies.

The five-year deal is Regeneron's second in the cell therapy space and will help bluebird build its oncology pipeline, which currently comprises clinical CAR T therapies bb2121...

Read the full 381 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >